Sunday, 20 September 2026European Markets

ESSILORLUXOTTICA And SARTORIUS STED BIO Have A High Dividend Yield And Return On Equity In The Healthcare Sector.

Loading stream...

(vianews) - essilorluxottica (el.pa) is among this list of stock assets with the highest dividend rate and return on equity on the healthcare sector.

financial asset price forward dividend yield return on equity
essilorluxottica (el.pa) €209.70 1.92% 6.3%
sartorius sted bio (dim.pa) €264.30 0.34% 8.15%

several euronext companies pay out dividends to its shareholders. the dividend yield is a dividend to price ratio showing how much a company pays out in dividends each year.

1. essilorluxottica (el.pa)

1.92% forward dividend yield and 6.3% return on equity

essilorluxottica société anonyme designs, manufactures, and distributes ophthalmic lenses, frames, and sunglasses in europe, the middle east, africa, latin america, the asia-pacific, and north america. it operates through professional solutions and direct to consumer segments. the company offers lens under the essilor, varilux, crizal, eyezen, stellest, xperio, transitions, ray-ban, oakley, barberini, kodak lens, nikon, shamir, eyexpert, iwear, humanware, and optifog brands. it also provides finishing equipment, vision performance screening, eye examination and refractions, fitting parameter measurements, and small tools and consumables under the essilor instruments brand; high-tech equipment for optical surfacing, polishing, measuring, coating, and finishing, as well as consumables, tools, and services under the satisloh brand. in addition, the company provides eyewear products under the ray-ban, oakley, persol, oliver peoples, vogue eyewear, arnette, alain mikli, costa, bliz, native, luxottica, sferoflex, bolon, molsion, dbyd, and unofficial and seen, as well as other licensed brands. in addition, the company designs, develops, markets, and maintains lens edging and mounting instruments for opticians and prescription laboratories; and optometry instruments for eyecare professionals, schools, occupational medicine centers, military, and other institutions. it wholesales its products to independent opticians, distributors, third-party e-commerce platforms, and large retail chains in the eyecare and eyewear industry; and sells directly to consumers through the network of brick and mortar retail network and its online channels. the company was formerly known as essilor international société anonyme and changed its name to essilorluxottica société anonyme in october 2018. essilorluxottica société anonyme was founded in 1849 and is headquartered in paris, france.

earnings per share

as for profitability, essilorluxottica has a trailing twelve months eps of €5.08.

pe ratio

essilorluxottica has a trailing twelve months price to earnings ratio of 41.28. meaning, the purchaser of the share is investing €41.28 for every euro of annual earnings.

return on equity

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 6.3%.

stock price classification

according to the stochastic oscillator, a useful indicator of overbought and oversold conditions, essilorluxottica's stock is considered to be oversold (<=20).

moving average

essilorluxottica's worth is higher than its 50-day moving average of €201.15 and way higher than its 200-day moving average of €180.30.

more news about essilorluxottica.

2. sartorius sted bio (dim.pa)

0.34% forward dividend yield and 8.15% return on equity

sartorius stedim biotech s.a. engages in the production and sale of instruments and consumables for the biopharmaceutical industry worldwide. the company offers various products, such as cell lines; cell culture media; bioreactors; advanced therapies; and a range of products for separation, purification, and concentration processes, as well as products and systems for storage and transportation of intermediate and finished biological products. it also provides cell cultivation, fermentation, separation, purification, and fluid management services; biolayer interferometry instruments; microbiology enumeration, sterility testing, and air monitoring instruments; pipette products; sensors and analyzers; biomolecule analysis tools; flow cytometry; batch and intensified chromatography systems; lab data and fleet management software; live cell imaging and analysis; surface plasmon resonance solutions; and weighing products. in addition, the company offers data analytics software for modeling and optimizing processes of biopharmaceutical development and production; process automation platform and software; and develops and produces transfection, as well as other dna/rna delivery reagents and plasmid dna. it serves manufacturers of medications, vaccines, foods, and chemicals, as well as research and development laboratories. the company was incorporated in 1978 and is headquartered in aubagne, france. as of december 31, 2023, sartorius stedim biotech s.a. operates as a subsidiary of sartorius ag.

earnings per share

as for profitability, sartorius sted bio has a trailing twelve months eps of €3.36.

pe ratio

sartorius sted bio has a trailing twelve months price to earnings ratio of 78.66. meaning, the purchaser of the share is investing €78.66 for every euro of annual earnings.

return on equity

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 8.15%.

more news about sartorius sted bio.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
AI Boom Hits a Fork: Slowdown Calls Clash with Capex Confidence as Markets Get Nervous
Dario Amodei's repeated calls for a global slowdown in frontier AI development, echoed by Microsoft's new humanist AI code of conduct and FTC antitrust caution, are being publicly rejected by Nvidia and Meta leadership even as hyperscaler spending draws fresh skeptical scrutiny (Wachter's analysis, Burry-style overbuilding worries) and weak guidance from Adobe and a post-slowdown-comment selloff in GE Vernova signal investor jitters. Meanwhile wealth and security effects of the AI race keep compounding — Zhang Yiming's fortune surging on AI-driven ByteDance value, a Chinese hacking firm weaponizing AI against stolen government secrets, and low-quality AI-generated products (an AI sitcom, a spam-flooding agent platform) fueling backlash even as adoption races ahead.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Berkshire Hathaway
Both facts report Berkshire Hathaway's cash position on 2026-01-01 with identical observation timestamps, but claim vastly different values: 380 billion USD vs 400 USD. These cannot both be true for the same entity at the same point in time. The magnitude of the discrepancy (a factor of ~10^9) rules out rounding, unit conversion, or methodological differences.
We flag conflicts openly ›
Recently verified
Checked against the original source
4,982
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,982 facts checked against source5,299 source documents archived
Query this data → isubstrate.com